The clinical application of targeting cancer through histone acetylation and hypomethylation

被引:88
作者
Gilbert, J
Gore, SD
Herman, JG
Carducci, MA
机构
[1] Louisiana State Univ, Ctr Hlth Sci, Stanley S Scott Canc Ctr, Div Hematol & Oncol, New Orleans, LA 70112 USA
[2] Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies, Baltimore, MD USA
[3] Sidney Kimmel Comprehens Canc Ctr, Div Canc Biol, Baltimore, MD USA
[4] Sidney Kimmel Comprehens Canc Ctr, Div Med Oncol, Baltimore, MD USA
关键词
D O I
10.1158/1078-0432.CCR-03-0297
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methods of gene inactivation include genetic events such as mutations or deletions. Epigenetic changes, heritable traits that are mediated by changes in DNA other than nucleotide sequences, play an important role in gene expression. Two epigenetic events that have been associated with transcriptional silencing include methylation of CpG islands located in gene promoter regions of cancer cells and changes in chromatin conformation involving histone acetylation. Recent evidence demonstrates that these processes form layers of epigenetic silencing. Reversal of these epigenetic processes and up-regulation of genes important to prevent or reverse the malignant phenotype has therefore become a new therapeutic target in cancer treatment.
引用
收藏
页码:4589 / 4596
页数:8
相关论文
共 122 条
[1]   Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein [J].
Aron, JL ;
Parthun, MR ;
Marcucci, G ;
Kitada, S ;
Mone, AP ;
Davis, ME ;
Shen, TS ;
Murphy, T ;
Wickham, J ;
Kanakry, C ;
Lucas, DM ;
Reed, JC ;
Grever, MR ;
Byrd, JC .
BLOOD, 2003, 102 (02) :652-658
[2]   DNA hypermethylation in tumorigenesis - epigenetics joins genetics [J].
Baylin, SB ;
Herman, JG .
TRENDS IN GENETICS, 2000, 16 (04) :168-174
[3]  
BEDFORD MT, 1987, CANCER RES, V47, P5274
[4]   The imprinting box of the mouse Igf2r gene [J].
Birger, Y ;
Shemer, R ;
Perk, J ;
Razin, A .
NATURE, 1999, 397 (6714) :84-88
[5]   PHENYLACETYLGLUTAMINE MAY REPLACE UREA AS A VEHICLE FOR WASTE NITROGEN-EXCRETION [J].
BRUSILOW, SW .
PEDIATRIC RESEARCH, 1991, 29 (02) :147-150
[6]   TREATMENT OF EPISODIC HYPERAMMONEMIA IN CHILDREN WITH INBORN-ERRORS OF UREA SYNTHESIS [J].
BRUSILOW, SW ;
DANNEY, M ;
WABER, LJ ;
BATSHAW, M ;
BURTON, B ;
LEVITSKY, L ;
ROTH, K ;
MCKEETHREN, C ;
WARD, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (25) :1630-1634
[7]   RESTORATION OF NITROGEN HOMEOSTASIS IN A MAN WITH ORNITHINE TRANSCARBAMYLASE DEFICIENCY [J].
BRUSILOW, SW ;
FINKELSTIEN, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (10) :1336-1339
[8]   Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells [J].
Byrd, JC ;
Shinn, C ;
Ravi, R ;
Willis, CR ;
Waselenko, JK ;
Flinn, IW ;
Dawson, NA ;
Grever, MR .
BLOOD, 1999, 94 (04) :1401-1408
[9]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[10]  
Carducci MA, 2001, CLIN CANCER RES, V7, P3047